Drug
Guselkumab (GUS)
Guselkumab (GUS) is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_4
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
NCT07310095
not_yet_recruiting
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
NCT07448402
recruiting
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT07444060
recruiting
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555
Clinical Trials (4)
Showing 4 of 4 trials
NCT07310095Phase 4
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
NCT07448402
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
NCT07444060
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT06249555
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4